Skip to main content
Premium Trial:

Request an Annual Quote

Genome Diagnostics Makes €1M Investment in CRISPR Diagnostics Startup Scope Biosciences

NEW YORK — Transplant diagnostics developer Genome Diagnostics (GenDx) has made a €1 million ($1.2 million) investment in startup Scope Biosciences, the Dutch companies said on Friday.

Scope Biosciences, a spinout of Wageningen University & Research founded in 2020, is developing a CRISPR-based diagnostic technology called ScopeDx that is aimed at infectious diseases including SARS-CoV-2. In August, the company's cofounders published details of the technology with academic collaborators in Nature Communications.

With the funding from GenDx, Scope said it will expand its R&D team and advance its ongoing partnerships. The companies also aim to explore the use of Scope's technology for transplant diagnostics.

"The proprietary ScopeDx CRISPR-diagnostic platform has shown its incredible potential in various applications in the last three years of its development, and with this investment we can bring the first ScopeDx products to the market," Scope CEO Niek Savelkoul said in a statement.

Earlier this year, GenDx received CE-IVD marking for its NGSgo-MX11-3 human leukocyte antigen typing product for organ and stem cell transplantation testing.

The Scan

Cell Signaling Pathway Identified as Metastasis Suppressor

A new study in Nature homes in on the STING pathway as a suppressor of metastasis in a mouse model of lung cancer.

Using Bees to Gain Insights into Urban Microbiomes

As bees buzz around, they pick up debris that provides insight into the metagenome of their surroundings, researchers report in Environmental Microbiome.

Age, Genetic Risk Tied to Blood Lipid Changes in New Study

A study appearing in JAMA Network Open suggests strategies to address high lipid levels should focus on individuals with high genetic risk and at specific ages.

Study Examines Insights Gained by Adjunct Trio RNA Sequencing in Complex Pediatric Disease Cases

Researchers in AJHG explore the diagnostic utility of adding parent-child RNA-seq to genome sequencing in dozens of families with complex, undiagnosed genetic disease.